Hematologic aspects of liver transplantation for XXXX with special reference to @entity6961 .

@entity1 @entity548 @entity1956 @entity1862 @entity117 @entity532 @entity49 @entity1503 @entity3181 @entity715 @entity18829 @entity6961 @entity1229
BACKGROUND: @entity1 who undergo orthotopic liver transplantation (OLT) for @entity3181 ( @entity3181 ) traditionally have been anticoagulated with warfarin postoperatively. Because a significant proportion of @entity3181 @entity1 are found to have an underlying @entity6961 ( @entity6961 ), antiplatelet therapy may be a more rational treatment strategy for this subgroup. METHODS: All @entity1 who underwent OLT for the diagnosis of @entity3181 at our institution through March 2000 were included in this analysis. Posttransplant therapy consisted of @entity1862 and @entity117 for those with MPDs. Standard anticoagulation or no antithrombotic treatment was given to @entity3181 @entity1 with other causes. @entity532 ( @entity715 and @entity548 ) and mortality were determined. RESULTS: Seventeen @entity1 underwent OLT for @entity3181 at our institution. The mean follow-up was 68.4 months. Two of seventeen @entity1 died; one @entity1 died of recurrent @entity715 (124 months after OLT) and the other @entity1 died of @entity1956 (7 months after OLT). Twelve @entity1 (71%) had evidence of a @entity6961 . Two of the @entity6961 @entity1 were treated with @entity1229 before the initiation of @entity1862 and @entity117 therapy. The remaining 10 @entity6961 @entity1 were placed on only @entity1862 and @entity117 after OLT. @entity18829 was used in place of @entity1862 in two @entity1 because of @entity1503 caused by the latter agent. The mean follow-up of this group of 10 @entity1 was 59.9 months. Only one @entity1 experienced recurrent @entity715 , which occurred more than 10 years after the original transplant. There were no major @entity548 complications and posttransplant liver biopsies were well tolerated. CONCLUSIONS: Antiplatelet therapy that consists of @entity1862 and @entity117 is a safe and effective alternative to anticoagulation to prevent recurrent @entity715 in @entity6961 @entity1 with @entity3181 after liver transplantation. For @entity1 with a @entity49 state corrected by OLT, antithrombotic therapy probably is not required. For those @entity1 with conditions not corrected by OLT or with idiopathic @entity3181 , anticoagulation or other therapy to control the @entity49 state should be given.
